Merck And Teva May Forgo Trial Over Actonel

Law360, New York (August 14, 2006, 12:00 AM EDT) -- The latest round in Merck & Co.’s long-running patent battle with generics maker Teva over bone strengthening compounds may end with a whimper rather than a bang, after both sides reportedly dropped their plans to go to trial.

The upcoming trial, which had been slated to begin in a few weeks, disappeared from the docket, according to Dow Jones.

Representatives for Merck and Teva were not immediately available for comment.

Attorneys for both companies either declined to comment or were immediately unavailable to discuss the matter....
To view the full article, register now.